WNT2B could help reduce inflammation in colitis
Official title: Determining the Anti-Inflammatory Mechanism and Therapeutic Potential of WNT2B in Colitis
Funded at Nemours Children's Hospital, Delaware · NIH-11364683 · Data updated 2026-11-12
A study at a children’s hospital will test whether increasing a protein called WNT2B can calm inflammation in the gut for people with colitis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nemours Children's Hospital, Delaware NIH-funded |
| Lab location | 1 site (Wilmington, United States) |
| Project start | September 1, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $719,124 |
| NIH project number | 1R01DK142812-01A1 |
| Project ID | NIH-11364683 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals with inflammatory bowel disease or colitis who may benefit from therapies targeting WNT2B pathways.
✕Less likely to help
Patients without colitis or inflammatory bowel conditions are unlikely to benefit from this research.
What this research studies
Researchers will explore how WNT2B works in the intestine to prevent inflammation and test whether boosting WNT2B could reduce colitis symptoms. They will study human samples and animal models to see how WNT2B interacts with NF-kB signaling and IL-6, and whether increasing WNT2B can lessen immune cell recruitment to the colon. The goal is to identify if WNT2B could be a safe, new therapy approach for human colitis. The work builds on findings from individuals with WNT2B loss of function to understand potential therapeutic benefits.
Why it matters
Potential benefit: If successful, this research could lead to new ways to treat human colitis by modulating WNT2B signaling.
How similar studies have gone: Previous studies suggest WNT2B involvement in controlling inflammation, supporting potential therapeutic relevance but human applications remain to be confirmed.
Where this research is happening
-
Nemours Children's Hospital, Delaware
Wilmington, United States Active
Researchers
- Principal investigator: Oconnell, Amy E — Nemours Children's Hospital, Delaware
- Study coordinator: Oconnell, Amy E
Related research
Other NIH-funded projects on the same topics.
-
How our genes and immune system affect C. difficile infections
This project looks at how a common human gene variant and immune factors influence the severity of C. difficile infections and whether targeting inflammation could help patients.
-
Outpatient pathway for severe ulcerative colitis in the right care setting
This study tests a safe, outpatient approach using an oral therapy and remote monitoring for people with acute severe ulcerative colitis to avoid hospitalization.
-
Fh15-based therapy to calm inflammation in sepsis and ulcerative colitis
A research project tests a molecule from a parasitic organism (Fh15) to reduce harmful inflammation in adults with sepsis or ulcerative colitis.
-
IMYX-3 treatment for ulcerative colitis
A new therapy approach called IMYX-3 aims to help adults with moderate to severe ulcerative colitis who have not responded well to current treatments.
-
Autoantibodies and ulcerative colitis: how avb6 antibodies may drive disease
This NIH grant aims to understand how antibodies against a gut cell protein (αvβ6) may actively contribute to ulcerative colitis and what that means for future treatments.
-
Selenium supplementation to help moderate-severe ulcerative colitis flare-ups
This grant tests whether giving selenium can help people with moderate to severe ulcerative colitis reduce flares and improve symptoms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.